Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 496 entries
View as:

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01753167 Org: User:
Start: 12/14/12 End: 10/15/14 Due: 10/15/15

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01075464 Org: User:
Start: 02/28/10 End: 04/30/13 Due: 04/30/14

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00047736 Org: User:
Start: 07/31/01 End: 07/31/03 Due: 07/31/04

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00096993 Org: User:
Start: 01/31/05 End: 09/30/07 Due: 09/30/08

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01375842 Org: User:
Start: 06/21/11 End: 09/30/18 Due: 09/30/19

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01519804 Org: User:
Start: 04/30/12 End: 09/30/15 Due: 09/30/16

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01487239 Org: User:
Start: 12/31/11 End: 01/31/12 Due: 01/31/13

A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01139723 Org: User:
Start: 06/30/10 End: 08/31/14 Due: 08/31/15

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02742779 Org: User:
Start: 09/15/15 End: 06/07/17 Due: 06/07/18

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00496132 Org: User:
Start: 08/27/07 End: 06/17/09 Due: 06/17/10

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Phase: N/A Priority: Normal
NCT ID: NCT00379795 Org: User:
Start: 04/30/05 End: 09/30/08 Due: 09/30/09

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT00137969 Org: User:
Start: 05/10/05 End: 08/25/08 Due: 08/25/09

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT03060538 Org: User:
Start: 03/05/17 End: 12/13/19 Due: 12/13/20

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase: N/A Priority: Normal
NCT ID: NCT06979336 Org: User:
Start: 08/08/25 End: 10/31/28 Due: 10/31/29

Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

Phase: N/A Priority: Normal
NCT ID: NCT05232929 Org: User:
Start: 03/29/22 End: 12/31/26 Due: 12/31/27

A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00251459 Org: User:
Start: 11/30/05 End: 09/30/07 Due: 09/30/08

An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g

Phase: N/A Priority: Normal
NCT ID: NCT00109187 Org: User:
Start: 06/30/02 End: 04/30/03 Due: 04/30/04

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT05224102 Org: User:
Start: 02/28/22 End: 02/28/27 Due: 02/28/28

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04566003 Org: User:
Start: 10/26/20 End: 06/27/23 Due: 06/27/24

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00932373 Org: User:
Start: 04/30/06 End: 06/30/09 Due: 06/30/10

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02748642 Org: User:
Start: 04/07/16 End: 06/14/17 Due: 06/14/18

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00130728 Org: User:
Start: 06/08/05 End: 12/23/19 Due: 12/23/20

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Phase: N/A Priority: Normal
NCT ID: NCT00336973 Org: User:
Start: 05/31/06 End: - Due: -

A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00954642 Org: User:
Start: 08/31/09 End: 12/31/11 Due: 12/31/12

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Phase: N/A Priority: Normal
NCT ID: NCT02927301 Org: User:
Start: 04/20/17 End: 09/05/23 Due: 09/05/24